These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37336294)

  • 1. Nitrite decreases sickle hemoglobin polymerization in vitro independently of methemoglobin formation.
    Almeida LEF; Smith ML; Kamimura S; Vogel S; de Souza Batista CM; Quezado ZMN
    Toxicol Appl Pharmacol; 2023 Aug; 473():116606. PubMed ID: 37336294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
    Demers M; Sturtevant S; Guertin KR; Gupta D; Desai K; Vieira BF; Li W; Hicks A; Ismail A; Gonçalves BP; Di Caprio G; Schonbrun E; Hansen S; Musayev FN; Safo MK; Wood DK; Higgins JM; Light DR
    Blood Adv; 2021 Mar; 5(5):1388-1402. PubMed ID: 33661300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
    Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
    Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.
    Gopalsamy A; Aulabaugh AE; Barakat A; Beaumont KC; Cabral S; Canterbury DP; Casimiro-Garcia A; Chang JS; Chen MZ; Choi C; Dow RL; Fadeyi OO; Feng X; France SP; Howard RM; Janz JM; Jasti J; Jasuja R; Jones LH; King-Ahmad A; Knee KM; Kohrt JT; Limberakis C; Liras S; Martinez CA; McClure KF; Narayanan A; Narula J; Novak JJ; O'Connell TN; Parikh MD; Piotrowski DW; Plotnikova O; Robinson RP; Sahasrabudhe PV; Sharma R; Thuma BA; Vasa D; Wei L; Wenzel AZ; Withka JM; Xiao J; Yayla HG
    J Med Chem; 2021 Jan; 64(1):326-342. PubMed ID: 33356244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.
    Quezado ZMN; Kamimura S; Smith M; Wang X; Heaven MR; Jana S; Vogel S; Zerfas P; Combs CA; Almeida LEF; Li Q; Quezado M; Horkayne-Szakaly I; Kosinski PA; Yu S; Kapadnis U; Kung C; Dang L; Wakim P; Eaton WA; Alayash AI; Thein SL
    Blood Cells Mol Dis; 2022 Jul; 95():102660. PubMed ID: 35366607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrosyl hemoglobin formation from nitrite in normal and sickle blood.
    Poudel L; Alipour E; Suriany S; Liu H; Baker SR; Karunarathna T; George A; Detterich J; Kim-Shapiro DB
    Free Radic Biol Med; 2024 Nov; 225():316-322. PubMed ID: 39389210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.
    Head CA; Brugnara C; Martinez-Ruiz R; Kacmarek RM; Bridges KR; Kuter D; Bloch KD; Zapol WM
    J Clin Invest; 1997 Sep; 100(5):1193-8. PubMed ID: 9276736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Aptamers That Bind to Sickle Hemoglobin and Inhibit Its Polymerization.
    Purvis SH; Keefer JR; Fortenberry YM; Barron-Casella EA; Casella JF
    Nucleic Acid Ther; 2017 Dec; 27(6):354-364. PubMed ID: 29039727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.
    Brittenham GM; Schechter AN; Noguchi CT
    Blood; 1985 Jan; 65(1):183-9. PubMed ID: 3965046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GBT440 Inhibits Sickling of Sickle Cell Trait Blood Under
    Dufu K; Lehrer-Graiwer J; Ramos E; Oksenberg D
    Hematol Rep; 2016 Sep; 8(3):6637. PubMed ID: 27757216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
    Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle Cell Hemoglobin in the Ferryl State Promotes βCys-93 Oxidation and Mitochondrial Dysfunction in Epithelial Lung Cells (E10).
    Kassa T; Jana S; Strader MB; Meng F; Jia Y; Wilson MT; Alayash AI
    J Biol Chem; 2015 Nov; 290(46):27939-58. PubMed ID: 26396189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.
    Papageorgiou DP; Abidi SZ; Chang HY; Li X; Kato GJ; Karniadakis GE; Suresh S; Dao M
    Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9473-9478. PubMed ID: 30190429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
    Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
    Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.
    Shrestha A; Chi M; Wagner K; Malik A; Korpik J; Drake A; Fulzele K; Guichard S; Malik P
    Blood Adv; 2021 May; 5(9):2385-2390. PubMed ID: 33944896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfated non-anticoagulant heparin derivative modifies intracellular hemoglobin, inhibits cell sickling in vitro, and prolongs survival of sickle cell mice under hypoxia.
    Abdulmalik O; Darwish NHE; Muralidharan-Chari V; Taleb MA; Mousa SA
    Haematologica; 2022 Feb; 107(2):532-540. PubMed ID: 33567814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Established and experimental treatments for sickle cell disease.
    De Franceschi L; Corrocher R
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.